FibroGen Inc
NASDAQ:FGEN
FibroGen Inc
Revenue
FibroGen Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
FibroGen Inc
NASDAQ:FGEN
|
Revenue
$147.8m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
4%
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
FibroGen Inc
Revenue Breakdown
Breakdown by Geography
FibroGen Inc
Total Revenue:
147.8m
USD
|
China:
109.4m
USD
|
Japan:
15.9m
USD
|
United States:
13m
USD
|
Europe:
9.5m
USD
|
Breakdown by Segments
FibroGen Inc
See Also
What is FibroGen Inc's Revenue?
Revenue
147.8m
USD
Based on the financial report for Dec 31, 2023, FibroGen Inc's Revenue amounts to 147.8m USD.
What is FibroGen Inc's Revenue growth rate?
Revenue CAGR 10Y
4%
Over the last year, the Revenue growth was 5%. The average annual Revenue growth rates for FibroGen Inc have been -6% over the past three years , -7% over the past five years , and 4% over the past ten years .